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The daily rhythm of cortisol secretion is relatively stable and primarily under the inﬂuence of the circadian clock. Nevertheless,
several other factors aﬀect hypothalamo-pituitary-adrenal (HPA) axis activity. Sleep has modest but clearly detectable modulatory
eﬀects on HPA axis activity. Sleep onset exerts an inhibitory eﬀect on cortisol secretion while awakenings and sleep oﬀset are
accompanied by cortisol stimulation. During waking, an association between cortisol secretory bursts and indices of central
arousal has also been detected. Abrupt shifts of the sleep period induce a profound disruption in the daily cortisol rhythm,
while sleep deprivation and/or reduced sleep quality seem to result in a modest but functionally important activation of the
axis. HPA hyperactivity is clearly associated with metabolic, cognitive and psychiatric disorders and could be involved in the well-
documented associations between sleep disturbances and the risk of obesity, diabetes and cognitive dysfunction. Several clinical
syndromes, such as insomnia, depression, Cushing’s syndrome, sleep disordered breathing (SDB) display HPA hyperactivity,
disturbed sleep, psychiatric and metabolic impairments. Further research to delineate the functional links between sleep and HPA
axisactivityisneededtofullyunderstandthepathophysiologyofthesesyndromesandtodevelopadequatestrategiesofprevention
and treatment.
1.Introduction
The release of nearly every hormone in humans is character-
ized by daily oscillations that result mainly from the interac-
tion between circadian rhythmicity and the sleep-wake cycle.
Circadian rhythms are generated by the endogenous master
pacemaker located in the paired suprachiasmatic nucleus
(SCN) of the hypothalamus and are kept entrained to the
local conditions by environmental timing cues; the most
important of these cues is light, that signaled to the SCN by
direct input from the retina via the retinohypothalamic tract
[1]. In addition to the master clock in the SCN, circadian
oscillatorshavebeenfoundinanumberofperipheraltissues,
such as liver, heart, lung, skeletal muscle, and adrenal glands
[2, 3].
Apart from circadian rhythmicity and sleep-wake cycle,
plentyofotherfactorswhichtendtorecuratregular24-hour
intervals, such as postural changes, food intake, exposure to
light and dark, have an inﬂuence on daily hormonal changes.
Given the close interaction of these periodic factors,
the study of the impact of each single component, and
in particular of sleep, on the hormonal proﬁles has faced
several methodological problems: sleep is, indeed, a period
of fasting, associated with changes in posture and light
exposure. Furthermore, the tight concordance of habitual
sleep and wake times with certain circadian phases has made
it diﬃcult to distinguish sleep and circadian eﬀects.
Hence, speciﬁc protocols have been designed to disso-
ciate the contribution of the alternation of sleep and wake
states from that of circadian process on 24-hour rhythms of
hormonalrelease.Themostcommonstudyprotocolsinvolve
shifts of the sleep period (with volunteers kept awake at
night and allowed to sleep at diﬀerent times of the day),
sleep deprivation, including constant routine conditions (in
which human volunteers remain awake for 30–60 hours, in
a semirecumbent position, in dim light and receive frequent
small identical meals) [4] and ultradian protocols (in which
subjects live on a very short “day” such as a 20 or 90 or 1802 International Journal of Endocrinology
minutes “day,” with 2/3 of the time awake and 1/3 of the time
asleep) [5–7].
2.Physiology of Hypothalamo-Pituitary-
Adrenal (HPA) Axis
The hypothalamo-pituitary-adrenal (HPA) axis is the major
neuroendocrine mediator of the stress response. A stressful
stimulus perceived by the senses ultimately induces the
release of CRH from the paraventricular nucleus (PVN) of
thehypothalamus.CRHstimulatesthereleaseofACTHfrom
the anterior pituitary and ACTH subsequently initiates the
liberation of glucocorticoids from the adrenal cortex. Corti-
sol has numerous actions, including feedback inhibition at
the level of the PVN and the anterior pituitary to control
CRH or ACTH synthesis and release. In addition, the HPA
axis receives relevant feedback from other areas of the brain,
such as the hippocampus and amygdala [8]. An important
interplay is also the excitatory reciprocal interaction between
the HPA axis and the brainstem sympathetic locus coeruleus
(LC)-norepinephrine (NE) system: CRH activates the LC;
in turn, NE, a known wake-promoting neurotransmitter,
activates hypothalamic CRH [9, 10].
The basal activity of the HPA axis displays a clear daily
rhythm: the 24-hour proﬁles of peripheral levels of ACTH
and cortisol occur in close parallelism and are characterized
by high levels in the early morning (acrophase), a decline
throughout the day, with a prolonged period of low levels
(quiescent period), centered around midnight (nadir), and a
rapid rise during the second half of the night. The amplitude
of the circadian oscillation is generally deﬁned as 50% of
the diﬀerence between the value of the acrophase and the
value of the nadir [11–13]( Figure 1). The nocturnal onset
of the cortisol rise and the morning peak may be seen as the
response to an endogenous stimulus driven by the circadian
clock, as it is suggested by the fact that the onset of the
cortisolrisetakesmanydaystoadapttoanabruptshiftofthe
sleep-wake and light-dark cycle [14]. The daylong cortisol
decline may represent the rate of recovery of the axis from
this endogenous challenge.
The results of constant routine, shifted sleep, and
ultradian schedule experiments have revealed prominent
endogenous circadian components in this well-characterized
and highly reproducible daily rhythm. As a conﬁrmation,
lesions of the SCN in rats result in the loss of corticosteroid
periodicity [15, 16]. The SCN shows, indeed, direct and
indirect projections (mainly via the subparaventricular zone
and the dorsomedial nucleus of the hypothalamus) to
the PVN [17, 18]. In addition, signiﬁcant evidence now
points to a neural SCN-adrenal gland connection, via the
autonomic nervous system and independent from the HPA
axis activation [19, 20]: this multisynaptic pathway from the
SCNtotheadrenalglandisabletotransmitlightinformation
to the adrenal glands, modulating corticosterone release
without changes in ACTH secretion [21] .M o r e o v e r ,ar o l e
in the circadian regulation of glucocorticoid secretion is
probabily played by an intrinsic circadian oscillator in the
adrenal glands: indeed, a study by Valenzuela and colleagues
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Figure 1: 24-hour individual cortisol proﬁle (solid line).The
smoothing curve (dotted line) is calculated to determine the
minimum (nadir), the maximum (acrophase), the onset of the
circadian rise, and the amplitude (50% of the diﬀerence between
the acrophase and the nadir) of the cortisol proﬁle. The black bar
represents the sleep period.
has recently demonstrated the rhythmic expression of clock
genesintheadrenalcortexofadiurnalprimate[22].Notably,
theoscillationofthetranscriptionalexpressionoftheadrenal
clock genes, accompanied by rhythmic expression of the
steroidogenic enzyme 3-beta-hydroxysteroid dehydrogenase,
was directly modulated by melatonin, shown to be a potent
time signal for the entrainment of peripheral circadian
oscillators, but was also maintained for 36 hours in cultured
adrenal explants, independently from the SCN oscillations.
The distinct circadian pattern of cortisol secretion may
be driven not only by circadian oscillators, but also by
metabolicfactors.TheHPAaxisplaysakeyroleinmobilizing
energy resources in conditions of reduced energy supply,
such as during hypoglycemia [23]. In response to HPA
axis activation, both liver and kidney increase endogenous
glucose production, ensuring suﬃcient glucose supply to
glucose-dependent organs, in particular the brain [24].
Correspondingly, mild transient hyperglycemia has been
shown to suppress HPA secretory activity in rats [25]. In
a recent study, nocturnal glucose administration in young
healthy males signiﬁcantly reduced the early morning rise
in ACTH and cortisol concentrations, regardless of whether
the subjects were asleep or awake, supporting the view that
increasing energy demands of the brain toward the end of
the night essentially contribute to the early morning peak in
the HPA axis activity [26].
T h ei m p a c to fa g ea n ds e xo nH P Af u n c t i o nh a sb e e n
an object of great interest and a matter of debate. Most
early studies investigating this topic, limited by small sample
sizes and heterogeneous composition, seemed to indicate
that there are no major sex and age diﬀerences in basal
functioning of the HPA axis [27–29]. However, aging has
been more often associated with an hyperactivation of the
axis in response to a stimulus: interestingly, what appears to
be more aﬀected is the ability of the axis to recover fromInternational Journal of Endocrinology 3
a challenge (resiliency), rather than the rate of the initial
response or the magnitude of the response [29, 30].
A study that analyzed almost 200 temporal proﬁles of
plasma cortisol from men and women, with ages from young
adulthood to late senescence, found, indeed, subtle but
substantial sex and age-related diﬀerences [31]( Figure 2).
In young adulthood, women appeared to have, compared
to men, lower 24-hour mean cortisol levels, a longer qui-
escent period (that started earlier and ended later), a lower
acrophase, and a lower absolute amplitude of the circadian
variation. Therefore, the female response to the circadian
signal appeared to be slower and of lesser magnitude than
in men and the recovery from the morning peak more
rapid with a longer quiescent period; a modulatory role of
estrogens in the greater resiliency of the HPA axis observed
i np r e m e n o p a u s a lw o m e nc a n n o tb er u l e do u ta n dm i g h tb e
involved in their lower rate of cardiovascular risk compared
to men. In the same study, aging was associated, in both
sexes, with a progressive increase of 24-hour mean levels
from the 2nd to the 8th decade, associated with a shorter
quiescent period and higher nadir values. These ﬁndings
are consistent with the reported association of aging with
an impairment in the inhibitory feedback mechanisms and
in the ability of the system to turn oﬀ the signal after the
morning stimulation [29]. A sex diﬀerence in the eﬀects
of aging on HPA function was apparent as in women, but
not in men, an increase in the level of the acrophase was
detected, as expression of increased responsiveness of the
axis;moreover,thereductioninthedurationofthequiescent
period appeared to be even sharper in women than in
men. Sleep complains in older adults are more common
in women than in men and this could play a role in the
greater female reduction of the quiescent period. Of note,
the most common sleep disorder, obstructive sleep apnea, is
as prevalent in older women as in older men. In addition,
the timing of the nadir and of the onset of the nocturnal
cortisolriseareadvancedinolderadultsofbothsexesandthe
circadian amplitude, when expressed as a percentage of the
24-hour mean level, is decreased: hence, during senescence
a progressive advance of circadian phase seems to occur,
associated with a loss of strength of the circadian signal.
Another recent protocol investigated the eﬀect of age,
gender and BMI on the pulsatile pattern of secretion
of ACTH and cortisol [32]. In this study, mean ACTH
concentrations, basal and pulsatile ACTH secretion directly
correlated with BMI and were higher in men than in women,
after controlling of BMI. The secretory regularity of ACTH
and cortisol was also evaluated with approximate entropy
(ApEn) statistic; the univariate ApEn quantiﬁes the orderli-
ness of a single hormone release, while the bivariate cross-
ApEn quantitates the relative pattern synchrony of coupled
time series: increased randomness of coupled hormonal
secretionpatternsisinterpretedasreﬂectingweakerfeedback
and feedforward control mechanisms [33]. ApEn analysis
revealed that greater age is associated with more irregular
patterns of cortisol, but not ACTH secretion, suggesting
that aging might alter intra-adrenal paracrine or neurogenic
mechanisms that modulate glucocorticoid secretion. In
addition,inmen,ACTH-cortisolfeedforwardsynchronyand
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Figure 2: Eﬀects of age and sex on cortisol proﬁle: Mean 24-hour
(+ or − SEM) cortisol proﬁles in men (left proﬁles) and women
(right proﬁles) for 2 age groups that is, 50 years of age and older
(solid lines) and 20 to 29 years old (hatched lines). (adapted from
Van Cauter [30])
cortisol-ACTH feedback synchrony both decline with age,
as quantiﬁed by cross-ApEn, denoting a deterioration of
coordinate control of ACTH and cortisol secretion patterns.
3. Effects of Normal Sleep on HPA Axis
Although modest, eﬀects of sleep on cortisol proﬁle are
clearly present and have been well documented.
Sleep is a dynamic process characterized by the alterna-
tion between two diﬀerent states: REM and non-REM sleep
(NREM). NREM sleep is further classiﬁed into 3 diﬀerent
stages of increasing intensity (stage 1, 2, and slow wave sleep,
or SWS). Each sleep stage has characteristic EEG frequencies
and waveforms. During REM sleep the EEG resembles that
of stage 1, with relatively low amplitude, mixed frequency
waveforms; muscle tone is inhibited and eye movement
are present. NREM sleep includes a variably synchronous
cortical EEG: in particular SWS exhibits high-amplitude
delta frequency (0.5–4.5Hz) oscillations as a deﬁning feature4 International Journal of Endocrinology
and are considered to have a fundamental role in the
restoration of cognitive, emotional, and metabolic functions.
Some changes in cortisol proﬁle seem to be sleep-state
dependent, others may be related to speciﬁc sleep stages.
3.1. Impact of Sleep Onset and Oﬀset. Sleep onset exerts a
modest inhibitory eﬀect on cortisol proﬁle that persists for
1-2 hours. This was evident in subjects undergoing a 3-hour
sleep-wakecycle[34],insubjectsreversingthephaseofsleep-
wake cycle by 180
◦ [35] and during temporal isolation (free
running condition) [36]. Under free-running conditions,
sleep is generally initiated at a much later phase of the
endogenouscircadiancortisolrhythm,thatis,aftertherising
phaseofcortisolhasbegun;inthiscasesleeponsetinterrupts
the rise of cortisol and inhibits its secretion for 1–3 hours. In
a similar way, sleep onset during habitual wake time lowers
cortisol levels [37]. In a study that compared the eﬀect of
nighttime sleep (sleep period 2300–0700) with daytime sleep
(sleep period 0700–1500, that is, sleep onset at the peak of
corticotropic activity), a transient decrease in cortisol levels
at the time of sleep onset was observed [13].
An inﬂuence of sleep-wake transitions on cortisol secre-
tion is also detectable during nocturnal awakenings which
are consistently associated with a transient elevation of
cortisol levels, followed by temporary inhibition of cortisol
secretion [38].
Similarly, the ﬁnal morning awakening elicits a rapid
and marked rise in cortisol levels, augmenting the circadian
acrophase of cortisol concentrations, but in contrast to noc-
turnal awakenings, the elevation of cortisol levels associated
with ﬁnal morning awakening persists for about one hour. In
addition, it is detectable independently of the time and the
mode of awakening (naturally or induced) [39], both in long
and short sleepers [40]. In the previously mentioned work
from Weibel et al. the acrophase of cortisol occurred at the
same time in the morning both in nighttime sleepers and
in daytime sleepers, demonstrating the strength of circadian
rhythmicity, but the amplitude of the morning pulse was
smaller if the subjects were asleep [13].
3.2. Modulatory Eﬀects of Sleep Stages. A consistent temporal
association between low cortisol levels and high SWS has
been demonstrated [41]. The inhibitory eﬀect that sleep
onset seems to exert on HPA axis has been mostly attributed
to SWS. Indeed the quiescent period of HPA activity,
although starting before sleep onset, occurs during the ﬁrst
half of the night when SWS is present to its greatest degree
[34, 35] and some authors have even hypothesized the
existence of an unknown factor, possibly GHRH secreted
during SWS, exerting inhibitory properties on corticotropic
activity [42]. Cortisol levels have been shown to decrease
in the ﬁrst 20 minutes after the onset of SWS [41]; in
addition,astudythatcomparedmorningsleepafteraregular
night of sleep, with morning recovery sleep after a night
of sleep deprivation, found increased SWS and decreased
cortisol levels in the latter condition [43], in agreement
with the hypothesis of an inhibitory role of SWS on cortisol
secretion. Furthermore, the response of ACTH and cortisol
to a stimulus (CRH administration, alone or in association
withvasopressin)hasbeenshowntobebluntedifthetestwas
performed during nighttime sleep, and in particular during
SWS, compared with nighttime wakefulness [44, 45].
Nevertheless, some authors have questioned the direc-
tion of the inverse link found between cortisol and SWS,
suggesting that a decreased HPA tone may promote sleep
deepening and, conversely, that increasing cortisol levels may
prevent the occurrence of SWS [13, 46]. Gronﬁer et al,
investigated the relationship between cortisol secretion and
slow-wave activity (SWA), the spectral power in the low
frequency range of the EEG (0.5–4.5Hz), that is considered a
stable trait dependent marker of the intensity of SWS. These
authors showed that, during the period of pulsatile release,
the cortisol secretory variations were concomitant with or
anticipated opposite variations in SWA, by 10–20 minutes
[47], suggesting the existence of a common central control.
An association between REM sleep and periods of low
adrenal cortex secretory activity has been reported [48]a n d
it has been shown that a signiﬁcant proportion of REM sleep
phases starts at a time of stable or decreasing cortisol levels,
but may persist after cortisol increases again [41]. In a study
investigating simultaneous chronological changes in sleep
duration and quality and in the 24-hour cortisol proﬁles
from young adulthood to old age, it was observed that a
decrease in the amount of REM sleep (stable and unchanged
until 50 years of age, decreased by approximately 50% in late
life compared with young adulthood) occurred in synchrony
with an elevation of evening cortisol levels. A trend for an
association between lower amounts of REM sleep and higher
evening cortisol concentrations, independently of age, was
also detected [49].
The association between cortisol secretion and speciﬁc
sleep stages has also been investigated in relation to memory
consolidation. It is well known that a central cognitive
function of sleep is to consolidate newly acquired memories
for long-term storage [50] and, moreover, diﬀerent sleep
stages seem to be implicated in the consolidation of diﬀerent
types of memory [51]. Retention of declarative memory
critically depends on the integrity of the hippocampus
and has been shown to beneﬁt speciﬁcally from early
nocturnal sleep, in which SWS predominates and cortisol
concentrations are minimal [52, 53]. Consistent with a role
for quiescent cortisol release in this process, hippocampus-
dependent declarative memory has been impaired by the
infusion of a low dose of cortisol during a period of early
SWS-rich sleep [54]. A similar result has been achieved
with the administration of the glucocorticoid receptor (GR)
agonist dexamethasone [55]. Thus, inhibition of cortisol
secretion and in particular inactivation of GRs appear to be
critical for hippocampus-mediated formation of declarative
memories.
When declarative memory for highly emotional rather
than neutral material is assessed, the data point to a more
beneﬁcial inﬂuence of REM sleep which prevails during the
latenight,whencortisolconcentrationsrise[56].Declarative
memory for emotional events, although still hippocampus-
dependent, is under critical modulation by the amygdala
[57].Arecentrandomized,double-blind,placebo-controlled
study examined the eﬀect of the cortisol synthesis inhibitorInternational Journal of Endocrinology 5
metyrapone on sleep-associated consolidation of memory
for texts of either neutral and emotional valence [58].
Metyrapone suppressed cortisol concentrations, especially
theriseincortisolduringlatesleep,anddecreasedtimespent
in SWS, which was replaced by shallow NREM sleep. REM
sleep was preserved. While memory for the neutral texts was
reduced, interestingly metyrapone even ampliﬁed emotional
enhancement in text recall, which has been shown in many
clinical and neuroimaging studies to depend on the amyg-
dala [59–61]. Thus, the late night rise in cortisol appears
to dampen amygdala-dependent emotional processing and
could exert a protective function by preventing excessive
emotionality in memory.
Cortisol secretory pattern, in association with speciﬁc
EEG frequencies, has been studied not only during sleep,
but also during wake: during daytime wakefulness cortisol
release follows the increase in EEG absolute power of the
beta frequency band (13–35Hz) with a 10-minute delay
[62]; this ﬁnding has been subsequently conﬁrmed in a
more recent study [63] in which a signiﬁcant temporal
association has been found between cortisol secretory rate
and waking EEG absolute power in the gamma frequency
range (20–45Hz), in a group of young males not sleep
deprived. Given that high-frequency EEG over 20Hz is
considered a marker of daytime arousal [64], a functional
link between the regulatory mechanisms controlling the
HPA activity and the level of central arousal has been
hypothesized.
4.EffectsofShiftedSleepon HpaAxis
As mentioned before, one of the strategies to diﬀerentiate
between eﬀects of circadian rhythmicity and eﬀects of sleep-
wake homeostasis on physiological variables has been to
design studies of shifted sleep, in which volunteers are
submitted to a large sudden advance or delay in their dark-
light, rest-activity, sleep-wake cycle, similar to what occurs
in jet lag or shift work rotations. Hence, these protocols
allow for the eﬀects of circadian modulation to be observed
in the absence of sleep and for the eﬀects of sleep to be
observedatanabnormalcircadiantime.Themostimportant
external time cue, that aligns the circadian system with the
environment, is the light-dark cycle, and these experiments
take advantage of the fact that the circadian pacemaker takes
several days to adjust to an abrupt shift in the dark-light
cycle. The rate of re-entrainment of the biological rhythms
to the new environmental time has been recognized to be
diﬀerent among physiologic variables, being slower for those
mainly controlled by the circadian process, and faster for
those mainly under the sleep-wake homeostasis control [65].
In the cortisol proﬁle, the end of the quiescent period and
the onset of the daily rise are mostly under the control of
circadian rhythmicity, while the timing of the acrophase and
the amplitude of the diurnal variation are more inﬂuenced
by sleep-wake transitions. Indeed, in studies of real and
simulated jet-lag, the synchronization of the acrophase to
the new clocktime occurred faster than the adaptation of the
quiescent period [14, 66].
4.1. Delay of the Sleep-Wake Cycle. The eﬀect of an abrupt 8-
hour delay of the sleep-wake cycle on plasma cortisol proﬁles
wasinvestigatedinastudydesignedtomimicwestwardtravel
across eight time zones [67] .T h ep r o t o c o li n v o l v e dat h r e e -
day period of habituation in which the subjects followed a
standardized schedule with ﬁxed meal times and sleep time
(23:00–7:00). On day 4, baseline 24 hours hormonal proﬁles
starting at 18:00 and sleep recordings were obtained. At the
end of the baseline sampling period, the subjects were kept
awake until 7:00 the next day, and then allowed to sleep
between 7:00 and 15:00, that is, 8 hours later than under
baseline conditions. Nocturnal wakefulness was enforced
in light intensity averaging 1.500lux, that is, very bright
indoor light. For the next four 24-hour spans the same
sleep schedule was maintained. Blood samples for 24-hour
hormonal proﬁles, starting at 2:00, and sleep recordings were
collected on the ﬁrst, third, and ﬁfth days of the shifted sleep
period. Cortisol proﬁles are shown in Figure 3.
On the ﬁrst day after the shift, profound disruptions in
the24-hourcortisolrhythmwerefound:areductionofmore
than 3 hours in the duration of the quiescent period resulted
in an increase of the 24-hour mean levels and in the advance
of the circadian onset. Both a higher nadir value, due to
the lack of the inhibitory eﬀect of sleep onset, and a lower
acrophase value, due to the lack of the stimulatory eﬀect
of awakening, were observed. As a consequence the relative
amplitude of the rhythm was reduced by approximately
40%. The timing of the acrophase was delayed by about
3 hours and 30minutes. On the third day, as a sign of
partial adaptation to the new schedule, the circadian onset
of cortisol was delayed by more than 5 hours, while the
timing of the acrophase was delayed by more than 6 hours.
Relative amplitude remained lower than at baseline. On day
5, the cortisol proﬁle had essentially been adapted to the new
schedule.
4.2. Advance of the Sleep-Wake Cycle. The impact on HPA
axis activity of an acute 8-hour advance of the rest-activity
cyclehasalsobeenexamined[68].Inthisstudy,eighthealthy
young subjects were studied for four consecutive days. The
ﬁrst day was a baseline condition and sleep was allowed
between 23:00 and 7:00; on day 2 the sleep period was
advanced, and subjects were allowed to sleep between 15:00
and 23:00. The same shifted cycle was maintained on day
3. Blood samples for plasma cortisol were collected for 68
consecutive hours, starting at 11:00, before the baseline night
(Figure 4). In the ﬁrst postshift period, compared with the
baseline proﬁle, the timing of the nadir was advanced by
about 3 hours and 20 minutes; the quiescent period was
markedly reduced mainly due to an advance of the oﬀset by
more than 3 hours. No shift in the timing of the acrophase
occurred, thus the duration of the rising phase of cortisol
secretion was increased by nearly 3 hours and presented
a biphasic pattern. No signiﬁcant changes were found in
the acrophase value. These changes, together with the slight
increase in the nadir values, resulted in a trend toward higher
24-hour mean levels. During the second postshift period
(day 3), minor signs of further adaptation of the cortisol
proﬁles were detected: there was no further advance of the6 International Journal of Endocrinology
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Figure 3: Eﬀect of an 8-hour sleep delay on cortisol proﬁles.
Mean 24-hour (+ SEM) cortisol proﬁles under baseline conditions
(bedtimes from 23:00 to 7:00), and one, three, ﬁve days after an 8-
hour delay of the sleep-wake and dark-light cycles (bedtimes from
7:00to15:00).Blackbarsrepresentthesleepperiods.(Adaptedfrom
Buxton et al. [67].)
timing of the nadir and only a minor additional advance
of the onset of the quiescent period. However a further
shift of almost 1 hour was observed for the oﬀset of the
quiescent period. Hence, the ﬁndings of this study showed
thatanabrupt8-houradvanceofthesleep-wake,rest-activity
and dark-light cycle results in a 3- to 4-hour advance of
the timing of the nadir and of the end of the quiescent
period, which are both reliable markers of central circadian
rhythmicity. In this protocol, however, there was a temporal
coincidence between the phase markers and the sleep-wake
and dark-light transition (at 23:00), which elicited robust
Clock time
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Figure 4: Eﬀect of an 8-hour sleep advance on cortisol proﬁles.
Mean (+ SEM) cortisol proﬁles obtained during 68 consecutive
hours including baseline conditions and 2 postshift periods, that
is, after an 8-hour advance of the sleep-wake and dark-light cycles.
Black bars represent the sleep periods whereas wake time was spent
in dim light conditions. (Adapted from Caufriez et al. [68].)
cortisol pulses. Thus, the advance of the timing of the nadir
and of the end of the quiescent period may only partly reﬂect
an advance of the circadian phase, because it could also be
partly due to the eﬀect of the awakening from the shifted
sleep. The lack of adaptation of the timing of the acrophase
to the new schedule has been interpreted as a consequence
of the biphasic pattern of the cortisol rise after the shift:
the ﬁrst peak induced by the sleep-awakening transition may
have delayed the subsequent circadian rise and prevented
the advance of the timing of acrophase. Therefore, despite
a relatively fast adaptation of some circadian markers, the
lack of adaptation of acrophase, the longer duration of the
risingphase,andtheshorterdurationofthequiescentperiod
resulted in elevated cortisol levels at the time of the usual
trough of the proﬁle. Circadian misalignment may lead to
central and peripheral deleterious consequences, such as
memory deﬁcit and insulin resistance [69–71].
5.Effects of Sleep Loss and
Sleep Disrupionon HPA Axis
Given the modest but clearly detectable inhibitory eﬀect
exerted by sleep onset on the activity of the HPA axis, it
has been hypothesized that sleep loss might increase cortisol
levels.Protocolsexaminingbothacutetotalsleepdeprivation
(prolonged wakefulness for 24 hours, 48 hours, or even 72
hours) and semichronic partial sleep restriction (reduction
of the nocturnal time in bed for a variable number of days)
have been designed to test this hypothesis.
5.1. Acute Total Sleep Loss. Several studies have reported
an elevation of cortisol levels both during the night of
total sleep deprivation [13, 35, 72] and, if wakefulness was
further prolonged, during the following day, particularly in
the afternoon and evening [63, 73]. The ﬁndings of high
glucocorticoid levels in a condition of acute sleep loss have
been interpreted as reﬂecting the stress of the eﬀort to
maintain wakefulness and is consistent with the positiveInternational Journal of Endocrinology 7
correlation found between high frequency EEG activity in
wake, indices of arousal, and cortisol release [63].
However, divergent ﬁndings have also been reported.
Indeed, some authors have reported no change [41, 43, 74,
75]o re v e nas l i g h td e c r e a s ei nc o r t i s o ll e v e l s[ 76, 77]a f t e r
one or several nights of total sleep deprivation. These dis-
crepancies could be due to a lack of control of experimental
conditions, such as physical activity and posture, and/or to
an insuﬃcient frequency of blood sampling; indeed, short
naps may have gone undetected and estimation of cortisol
levels with infrequent blood sampling are often inaccurate.
Findings of decreased cortisol levels after sleep deprivation
have been interpreted as related to an increase in fatigue
and sleepiness. Notably, the decrease in plasma or urinary
cortisol found by Kant et al. [77]a n d˚ Akerstedt et al. [76]
occurred after 48 hours or more of prolonged wakefulness.
Hence, a biphasic HPA response to sleep deprivation has
been suggested [63] where activation of the HPA axis, as part
of the stress response, may be one of the arousal mechanisms
recruited early on to adapt to sleep loss; however, when
wakefulness is prolonged, the increased sleep pressure may
eventually cause a blunting of the HPA axis activity.
Some protocols have examined cortisol proﬁles during
the recovery night after a night of total sleep deprivation.
Again contradictory results have been reported: while in
some studies cortisol secretion seemed to be almost unaf-
fected by recovery sleep following prolonged wakefulness
[78–80], Vgontzas et al. [81] found a signiﬁcant decrease
in plasma cortisol levels, that appeared to be negatively
correlated with the rebound increase of SWS. The timing of
the period of recovery sleep is likely to have played a role in
these conﬂicting ﬁndings.
5.2. Semichronic Partial Sleep Restriction. Recurrent partial
sleep restriction has become a widespread habit in modern
society [82] and its hormonal and metabolic consequences
have only begun to be appreciated.
The ﬁrst systematic study of HPA axis activity in a state
of sleep debt assessed the eﬀect of 6 consecutive nights of 4
hours in bed in eleven young men [83]. The sleep debt con-
dition was compared with a fully rested condition, obtained
after 6 nights of 12 hours in bed. Plasma and salivary cortisol
were measured under both conditions. The state of sleep
debt, as compared to the fully rested state, was associated
with elevated cortisol concentrations in the afternoon and in
the early evening and with a shorter quiescent period, due to
a delay in its onset by nearly 1.5 hour. In addition, the rate
of decrease of free cortisol concentrations in saliva between
16.00 hours and 21.00 hours was about six times slower in
the sleep-debt than in the fully rested condition. Nine of
the eleven subjects of the previous study participated, one
year later, in a separate protocol with 8-hour bedtime, using
the same experimental procedures. Interestingly, cortisol
evening levels observed under 8-hour bedtime condition
were intermediate between those measured under 4-hour
and 12-hour bedtime conditions [84]( Figure 5).
Consistent ﬁndings indicative of an elevation of evening
cortisollevelsfollowingpartialsleeplosshadbeenpreviously
reported after only 1 night of sleep restricted to 4 hours in
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Figure 5: Inverse “dose-response” relationship between evening
cortisol levels and sleep duration. Mean 24-hour (+ SEM) cortisol
proﬁlesandAUC(blackareas)under4hours,8hours,and12hours
bedtimes. Black bars represent the sleep periods. (Adapted from
Spiegel et al. [84].)8 International Journal of Endocrinology
bed [73]. In this study, plasma cortisol levels over the 1800–
2300 hour period were 37% higher on the day following the
night of restricted sleep than on the previous day, and the
onset of the quiescent period occurred 1 hour later.
Thus, sleep deprivation appears to be associated with an
elevation in evening cortisol levels that may reﬂect decreased
eﬃcacy of the negative feedback regulation of the HPA axis.
Even if modest, this elevation may result, under conditions
of chronic sleep loss, in a signiﬁcant glucocorticoid overload
and consequently expose the body to the central and
peripheral deleterious eﬀects associated with glucocorticoid
excess.
In this regard, it is notable that chronic short sleepers
have been found to have higher nocturnal cortisol levels
compared with chronic long sleepers [40], suggesting that,
even in the long term, mechanisms of adaptation and down-
regulation of the HPA axis fail to occur. In a cross-sectional
analysis of data collected from the Whitehall II study,
the relationship between self-reported sleep duration, sleep
disturbances, and salivary cortisol levels has been assessed in
a cohort of more than 2700 middle-aged men and women
[85]. Short sleep duration was associated with an acute
increased cortisol awakening response and both short sleep
duration and disturbances were independently associated
with a slower rate of decline of cortisol levels across the day
and thus with increased evening levels.
An increasing number of epidemiological studies have
reported an association between short sleep duration and
higher risk of developing obesity and type II diabetes [86–
89]. The evidence summarized above suggests that HPA axis
hyperactivitycouldbeoneofthemechanismsinvolvedinthe
pathogenesis of these metabolic impairments.
5.3. Impact of Disrupted Sleep Quality. Only a few experi-
mental studies have examined the eﬀect of changes in sleep
quality on activity of the HPA axis. Some of them were
designed to suppress speciﬁc stages of sleep, others involved
sleep fragmentation across all stages of sleep.
The two studies that examined the impact of SWS
suppression on the temporal proﬁles of cortisol secretion
had negative ﬁndings: the earlier study [90]c o n d u c t e di n
young men, compared the nocturnal cortisol proﬁle during
a baseline night with that observed during partial SWS sleep
suppression(between2300and0200).Themorerecentstudy
[91] investigated 24 hours cortisol proﬁles in a group of
young men and women after 2 nights of normal sleep and
after 3 nights of selective suppression of SWS throughout the
night. In both studies, suppression of SWS was achieved by
sending acoustic stimuli to the bedside whenever delta waves
occurred and both studies attempted to avoid complete
awakenings. Therefore stages of deep sleep were replaced
with more shallow sleep, without increase in wake after sleep
onset. No signiﬁcant changes in cortisol proﬁles were found.
Decreased cortisol levels have been reported in a study of
REMsuppression[92].However,REMsleepsuppressionwas
achieved through brief awakenings, resulting in a signiﬁcant
increase in wake time.
A recent experiment of sleep fragmentation led to
diﬀerent ﬁndings [93]. Following 2 nights of experimental
sleep fragmentation across all stages, an increase in morning
cortisol levels was observed, in association with a shift in
the sympatho-vagal balance, estimated from the analysis of
the heart rate variability towards an increase of sympathetic
nervous system activity, and a decrease in insulin sensitivity.
6.HPA AxisandSleepDisturbancesin
ClinicalSyndromes
While sleep loss and sleep disruption are generally thought
of as activating the HPA axis, there is in turn strong evidence
that elevated CRH tone increases sleep EEG frequency,
thereby decreasing SWS, and increasing light sleep and
wakefulness [94]. In addition, CRH reciprocally activates
the locus coeruleus/norepinephrine (LC/NE) system, one
of the most important components of the arousal systems
[95]. Consistently, CRH1 receptors, mediators of the CRH
action,havebeenextensivelystudiedaspotentialdrugtargets
and a large number of CRH1 receptors antagonists have
been developed for the treatment of stress-related diseases
as well as sleep disorders [96]. Glucocorticoids, on the
contrary, may exert a dual eﬀect on sleep, depending on
the prevailing concentrations: low levels of cortisol are
associated with mineralocorticoid receptor (MRs) binding
in the hippocampus, that mediate a negative feedback on
hypothalamic CRH secretion. In contrast, at higher cortisol
levels, glucocorticoid receptors (GRs) are activated, which
may exert either inhibitory or excitatory feedback on CRH,
depending on the location of the receptors. In times of stress,
amygdala GRs may be preferentially activated, increasing
CRH secretion, therefore promoting sleep disruption [8].
Moreover, it is well known that activation of HPA axis plays
an essential causative role in the pathogenesis of metabolic
and mood disorders that are often also associated with sleep
disturbances [97, 98].
Given these functional links, it is not surprising that
HPA hyperactivity, disturbed sleep, psychiatric disorders,
and metabolic impairment are characteristic features of
several clinical syndromes. We therefore describe below
the interactions between sleep and HPA activity in insom-
nia, depression, Cushing’s syndrome, and sleep disordered
breathing (SDB).
6.1. Insomnia. Insomnia is a sleep disorder characterized
by diﬃculties falling or staying asleep or having restorative
sleep, associated with daytime impairment or distress [99].
Even though it is one of the most commonly encountered
sleep disorders in medical practice, the understanding of
its neurobiological basis and etiology is still limited and
therefore even the treatment of this condition is challenging
and often unsatisfactory [100].
Despite the evidence linking sleep and HPA axis, and the
clearassociationbetweeninsomniaandperceivedstress[101,
102], of which the HPA axis is a major mediator, there is a
paucity of studies assessing HPA axis activity in this disorder.
An early study failed to show any diﬀerence in uri-
nary cortisol excretion between control and self-reported
poor sleepers [103]. However, the EEG recorded diﬀerenceInternational Journal of Endocrinology 9
between the two groups was only half an hour in total
sleep time: such a small diﬀerence may have prevented the
detection of alteration in cortisol secretion. On the contrary,
in a more recent experiment, 24-hour urinary free cortisol
excretion was positively correlated with polysomnographic
indices of sleep disturbance in a group of adult insomniacs
[104]. Moreover, a study that collected 24-hour plasma
ACTH and cortisol proﬁles in young insomniacs and in
matched healthy controls found mean ACTH and cortisol
levels higher in insomniacs than in controls, with the
stronger elevations observed in the afternoon, in the late
evening and in the early part of the night [105]( Figure 6).
In addition, within the insomniacs, those with a high degree
of sleep disturbance, compared with those with a low degree
of sleep disturbance, secreted a higher amount of cortisol,
particularly in the evening and in the nighttime periods.
It is still matter of debate if the activation of the HPA
system observed in insomnia is secondary to sleep loss or
is, on the contrary, a marker of increased central CRH
activity.Inthelattercase,theelevationofCRHtone,possibly
following the repeated exposure to a stress, such as in the
post traumatic stress disorder (PTSD), may be primarily
responsible for the sleep disturbance. Even though some
authors lean towards this second hypothesis, suggesting an
HPA axis dysfunction as causative factor in the pathogenesis
of insomnia [8, 105], a contribution of sleep loss to the
evening cortisol elevation seen in insomniacs, cannot be
ruled out. An intriguing and plausible model has been
proposed to explain the perpetuation of chronic insomnia.
In fact, evening cortisol levels while awake correlate with
the number of awakenings during the subsequent night in
subjects with and without insomnia [106, 107]. If elevated
HPA activity before sleep promotes sleep fragmentation,
sleep fragmentation and sleep loss have in turn been shown
to increase evening cortisol levels, as discussed before. Taken
together, these data suggest the occurrence of a vicious circle
that could be responsible for the chronicity of insomnia. Of
note, multiple studies have shown that insomnia precedes
and is a risk factor for the development of psychiatric
conditions, including depression and anxiety [101]. The
activation of HPA axis in chronic persistent insomnia might
play a role in the pathogenesis of these disorders.
6.2. Major Depression. Alterations of sleep architecture and
HPA axis are commonly observed in patients with major
depression.
Characteristic sleep-EEG ﬁndings in depressed patients
include disturbed sleep continuity, increased wakefulness,
shorter REM latency, and increased REM density [108–110].
Spectral analysis further reveals lower slow-wave activity
during the ﬁrst non-REM period [111].
Well-documented neuroendocrine changes in depressed
patients include increased cortisol levels, in particular at the
time of the cortisol nadir [112, 113], increased ACTH levels
[113], lack of inhibition of cortisol to the suppression test
with dexamethasone [114, 115] or exaggerated response of
ACTH and cortisol to the combined dexametasone+CRH
test [116]. An alteration of circadian rhythmicity, namely,
a phase advance of the ACTH and cortisol nadir has
b e e nf o u n di ns o m es t u d i e s[ 117, 118], but not in others
[119, 120].
It is still unclear if these neuroendocrine and EEG
alterations are a trait marker of depression, detectable
independent from the phase (relapse or remission) of the
syndrome or a state marker, able, therefore, to normalize
during periods of remission.
One report documented a normalization of both ACTH-
cortisol proﬁles and REM sleep in adult patients after
recovery [117], but in other studies, cortisol levels or the
response to Dex-CRH test were improved after recovery, but
pathological sleep-EEG persisted [121–123].
Interestingly, it has been hypothesized that the nature
and the extent of the alterations in HPA axis activity
and in sleep architecture may help to identify distinct
subtypes within major depression [124]. Indeed, an HPA
overdrive seems to be most consistently observed in patients
with melancholic features, associated with major sleep EEG
alterations (low amount of SWS, short REM latency, high
REMdensity).Incontrastpatientswithatypicalfeaturesmay
be characterized by reduced HPA activity, hypersomnia and
less consistent alterations of SWS and REM sleep [124, 125].
6.3. Cushing’s Syndrome. Endogenous Cushing’s syndrome
results from chronic exposure to excess glucocorticoids
produced by the adrenal cortex. It may be caused by an
excess of ACTH production (usually by pituitary adenomas,
less frequently by extrapituitary ACTH- or CRH-secreting
tumors) or it can result from the excess secretion of cortisol
byunilateraladrenocorticaltumors(benignormalignant)or
by bilateral adrenal hyperplasia or dysplasia [126].
Hallmarks of the Cushing’s syndrome are the loss of
the typical circadian rhythm of cortisol secretion [127]
associated with the peripheral and central consequences of
the glucocorticoid excess: metabolic impairments (hyper-
insulinism and insulin resistance decreased glucose toler-
ance, visceral adiposity, hyperlipidemia, and hypertension),
coagulopathy, osteoporosis, and increased risk of psychiatric
disorders (major depression, anxiety, mania, and cognitive
dysfunctions).
Only a few studies have assessed sleep by polysomnogra-
phy (PSG) in Cushing’s syndrome.
In a recent experiment that analyzed nocturnal cortisol
secretion in a group of patients with pituitary Cushing’s
syndrome compared with a group of matched healthy
subjects, adrenal secretory activity was shown to start
predominantly during periods of NREM sleep in both
groups. Thus, even though the normal nocturnal circadian
oscillation of pituitary-adrenal activity is absent or markedly
bluntedinCushingpatients,alinkbetweenpituitary-adrenal
activity and the ultradian rhythmicity of REM-non REM
sleep appears to be preserved [127].
Alterations of PSG recordings have been consistently
found in Cushing’s syndrome, conﬁrming the deleterious
eﬀects of glucocorticoids at high concentrations on sleep
architecture. A reduction of SWS has been reported [46,
128].Inonestudydisturbancesofsleepcontinuity(increased
sleep latency, enhanced waketime) and of REM sleep (short-
ened REM latency, elevated REM density) have been found10 International Journal of Endocrinology
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Figure 6: Cortisol rhythm under diﬀerent sleep conditions. (a) and (b): 24-hour (+ SEM) cortisol proﬁles under 4 hours (a) and 12 hours
(b) bedtimes (Adapted from Spiegel et al. [84]). (c) and (d): 24-hour (+ SEM) cortisol proﬁles in young insomniacs (c) and age, and BMI-
matched controls (d) (Adapted from Vgontzas et al. [105]). Black bars represent the sleep periods.
[128]. Interestingly, these sleep alterations are similar to
those occurring in major depression.
6.4. Sleep Disordered Breathing. Sleep disordered breathing
(SDB) and, in particular, obstructive sleep apnea (OSA) are
increasingly common conditions characterized by repetitive
episodesofhypopneaorapnea,duetothelossofmuscletone
in the upper airways; subsequent progressive hypoxemia and
hypercapnia occur, followed by autonomic and EEG arousal
aimed to open the airway and resume normal breathing.
However, as sleep occurs again, the cycle repeats itself,
throughout the night.
Majorsleepdisturbancesresultfromthisconditionwhen
untreated: total sleep time and sleep eﬃciency are reduced
and sleep is more fragmented; wake, stage 1 and stage 2 are
increased, SWS and REM sleep are markedly reduced [129,
130]. Treatment with continuous positive airway pressure
(CPAP), that represents at the moment the most eﬃcacious
therapy for sleep apnea, has been shown to improve sleep
architecture in SDB patients [131].
Moreover, important metabolic impairments are part of
the clinical features that characterize this syndrome: indeed,
SDB is associated with elevated body mass index (BMI),
hypertension, increased risk of diabetes, insulin resistance
and dyslipidemia [132]. Even though, until recently, it was
unclear if alterations in glucose metabolism and hyperten-
sion were the results of obesity or of SDB per se, there
is a growing evidence to indicate that SDB may represent
an independent risk factor in the pathogenesis of these
metabolic alterations [133–136].
The mechanisms that underlie this increased metabolic
riskarenotfullyunderstoodyet.Itislikelythatanincreasein
the sympathetic activity, secondary to the respiratory distress
[137] or to the sleep loss/fragmentation per se [91]p l a y sInternational Journal of Endocrinology 11
aroleinthedevelopmentofmetabolicmorbiditiesassociated
with SDB.
The role of HPA axis has also been investigated, with
the hypothesis of a hyperactivation of the axis, due to sleep
fragmentation and sleep loss. An additional activating factor
could be hypoxia, able to stimulate ACTH and cortisol
secretion both in animals and in humans [138–140].
Contradictory ﬁndings have been reported regarding the
eﬀects of SDB on the HPA system and the results are limited
by small sample sizes and methodological diﬀerences among
the studies, such as variable hours of sleep recording and
variable severity of SDB.
Elevated cortisol levels have been found in patients with
OSA present in some studies [141, 142] but not in others
[143, 144]. Responsiveness of ACTH to CRH administration
has been shown to be higher in obese patients without
OSA compared with lean subjects and to be even higher
in obese patients with OSA [145], probably as the result of
an alteration in the central control of ACTH secretion, as
well as of an impaired sensitivity to the negative feedback
action of glucocorticoids. In a recent study the existence of
a mild hypercortisolism in OSA patients has been suggested
by the ﬁnding of a blunted response of cortisol to the
dexamethasone suppression test [146].
The eﬀects of CPAP therapy on cortisol levels have
also been investigated. Some authors have reported that
CPAP does not reduce cortisol levels [147] or that acute
withdrawal of CPAP treatment does not result in an increase
in cortisol levels [148]. On the contrary, CPAP does reverse
hypercortisolemia according to other authors [149, 150],
particularlywithprolongeduse[142].Noteworthy,severalof
these studies were limited in that cortisol was measured at a
singletimepoint,andconsequentlydonotmeasurepotential
clinically important HPA axis and rhythm changes. Variable
compliance levels may also explain discrepant ﬁndings. In a
recent study that measured nocturnal cortisol proﬁles, sleep
apneainobesemencomparedwithnonapneicobesecontrols
was associated with an elevation of cortisol levels, which was
corrected after 3 months of CPAP use [151].
HPA hyperactivation, as result of sleep disturbance,
hypoxemia,s and autonomic activation, may play a signiﬁ-
cantroleinthedevelopmentofthemetabolicalterationsthat
characterize OSA. Given the impact of OSA on sleep archi-
tecture, it may contribute to the perpetuation of the sleep
disorder. Moreover, it may be a risk factor for insomnia and
depression, as both are associated with hypercortisolemia.
7. Conclusions
The interaction between sleep and the HPA axis is complex
and bidirectional. HPA hyperactivity and decreased sleep
duration/quality seem to be tightly linked in a vicious circle
and could play an essential causative role in the pathogenesis
of metabolic and mood disorders. Hypercortisolism, sleep
disturbances, metabolic and psychiatric impairments are
common features of several clinical syndromes, such as
insomnia, depression, Cushing’s syndrome, and SDB. The
exact understanding of the interaction between sleep phys-
iology and HPA activity appears to be a crucial prerequisite
to better elucidate the physiopathology of these syndromes
and may lead to new forms of prevention and treatment.
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